DE69901805T2 - Pharmazeutische zusammensetzung mit mutiertem tyrosin 353 ezrin - Google Patents

Pharmazeutische zusammensetzung mit mutiertem tyrosin 353 ezrin

Info

Publication number
DE69901805T2
DE69901805T2 DE69901805T DE69901805T DE69901805T2 DE 69901805 T2 DE69901805 T2 DE 69901805T2 DE 69901805 T DE69901805 T DE 69901805T DE 69901805 T DE69901805 T DE 69901805T DE 69901805 T2 DE69901805 T2 DE 69901805T2
Authority
DE
Germany
Prior art keywords
pharmaceutical composition
ezrin
mutated
tyrosin
tyrosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69901805T
Other languages
English (en)
Other versions
DE69901805D1 (de
Inventor
Monique Arpin
Tiziana Crepaldi
Alexis Gautreau
Daniel Louvard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut Curie
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut Curie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Institut Curie filed Critical Centre National de la Recherche Scientifique CNRS
Application granted granted Critical
Publication of DE69901805D1 publication Critical patent/DE69901805D1/de
Publication of DE69901805T2 publication Critical patent/DE69901805T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69901805T 1998-03-18 1999-03-18 Pharmazeutische zusammensetzung mit mutiertem tyrosin 353 ezrin Expired - Fee Related DE69901805T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/040,725 US6399584B1 (en) 1998-03-18 1998-03-18 Pharmaceutical composition containing ezrin mutated on tyrosine 353
PCT/EP1999/002054 WO1999047150A2 (en) 1998-03-18 1999-03-18 A pharmaceutical composition containing ezrin mutated on tyrosine 353

Publications (2)

Publication Number Publication Date
DE69901805D1 DE69901805D1 (de) 2002-07-18
DE69901805T2 true DE69901805T2 (de) 2003-03-06

Family

ID=21912598

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69901805T Expired - Fee Related DE69901805T2 (de) 1998-03-18 1999-03-18 Pharmazeutische zusammensetzung mit mutiertem tyrosin 353 ezrin

Country Status (6)

Country Link
US (2) US6399584B1 (de)
EP (1) EP1061941B1 (de)
AT (1) ATE218881T1 (de)
AU (1) AU3600199A (de)
DE (1) DE69901805T2 (de)
WO (1) WO1999047150A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2354241A (en) * 1999-09-17 2001-03-21 Rupert Donald Holms Regulatory/unfolding peptides of ezrin
CA2446458A1 (en) 2001-05-09 2002-11-14 Yale University Toll/interleukin-1 receptor adaptor protein (tirap)
AU2003257960A1 (en) * 2002-08-01 2004-03-03 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Cell modulation using a cytoskeletal protein
AU2004234076A1 (en) * 2003-04-30 2004-11-11 Laboratoires Serono Sa Beta-amyloid inhibitors and use thereof
WO2005060996A2 (en) * 2003-12-23 2005-07-07 Lauras As Method of altering the pka type i signalling pathway
ATE511848T1 (de) * 2004-08-25 2011-06-15 Us Gov Health & Human Serv Lebendige mikrobielle mikrobizide
CA2569080A1 (en) * 2006-11-20 2008-05-20 Institut Pasteur Anti-coronavirus molecules and their use in compositions and methods for treating and/or preventing infection caused by a coronavirus
WO2009103312A1 (en) * 2008-02-19 2009-08-27 Ludwig-Maximilians-Universität Ezrin, serpin b5, peroxiredoxin-2 and heat shock protein beta-1 as autoantigens for psoriasis and poststreptococcal diseases
US9127077B2 (en) 2009-09-23 2015-09-08 L'universite Paris Descartes Polypeptides and nucleic acids for treating ErbB2-dependent cancers

Also Published As

Publication number Publication date
US6399584B1 (en) 2002-06-04
WO1999047150A9 (en) 1999-11-18
ATE218881T1 (de) 2002-06-15
DE69901805D1 (de) 2002-07-18
US20020115633A1 (en) 2002-08-22
EP1061941B1 (de) 2002-06-12
EP1061941A2 (de) 2000-12-27
WO1999047150A3 (en) 2000-01-20
AU3600199A (en) 1999-10-11
WO1999047150A2 (en) 1999-09-23

Similar Documents

Publication Publication Date Title
ES2172654T3 (es) Uso de nsaid para el tratamiento de carcinomas de celulas escamosas de la cavidad oral u orofaringe.
NZ334124A (en) Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
MD960330A (ro) Compuşi nepeptidilici, compoziţie farmaceutică pe baza acestora, metodă de tratament
ID29393A (id) Komposisi pengobatan kanker dan metoda penggunaan minyak-minyak esensil tanaman alamiah
AP2001002129A0 (en) 5HT1 receptor agonists and metoclopramide for the treatment of migrane.
BR0307508A (pt) Composto, composição farmacêutica, e, métodos de tratamento ou prevenção de dor e inflamação e de tratamento de doença
HK1050860A1 (en) Nordihydroguaiaretic derivatives for use in treatment of tumors
ATE221881T1 (de) Tetralin-verbindungen mit multi-drugresistenz (mdr)-aktivitat
NO20004419L (no) Ny anvendelse
YU13301A (sh) Muskarinski agonisti i antagonisti
TR199800270T1 (xx) Kanser hastal�klar�n�n ilerlemesini �nlemede flukonazol kullan�m�.
DE69619052D1 (de) Feste, wasserfreie, pharmazeutische Zubereitungen für vaginale Verwendung
TR200001040T2 (tr) Kaşıntıyı önleme etkisi için bileşiklerin yeni bir kullanımı
DK0946157T3 (da) Topisk anvendelse af kappa-opioid agonister til behandling af øjensmerte
DE69901805D1 (de) Pharmazeutische zusammensetzung mit mutiertem tyrosin 353 ezrin
ATE240303T1 (de) 1,2,4-triazol-3-thion verbindungen
ZA947894B (en) Compounds for medicinal use
RS49599B (sr) Upotreba inhibitora h+, k+-atp-aze i glukokortikoida i farmaceutska formulacija
TR199802351T2 (xx) Topikal kullanım için bir veya birden fazla lokal anestezik ve anti-vajinit maddeler ihtiva eden anti-vajinit bileşimi.
NO983177L (no) Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft
AU1656997A (en) Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
UA48245C2 (uk) ЗАМІЩЕНІ 1,2,3,4-ТЕТРАГІДРО-2-ДИБЕНЗОФУРАНАМІНИ ТА 2-АМІНОЦИКЛОГЕПТА[B]БЕНЗОФУРАНИ, ФАРМАЦЕВТИЧНА ЛІКАРСЬКА ФОРМА ТА СПОСІБ ПІДВИЩЕННЯ АКТИВАЦІЇ 5-НТ<sub>1F</sub> РЕЦЕПТОРА У ССАВЦЯ
ATE500269T1 (de) Verbindungen mit wachstumshormon-freisetzenden eigenschaften
BG104914A (en) Paroxetine maleate
DE69231263T2 (de) Calcitonin enthaltende pharmazeutische Zusammensetzungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee